
    
      The primary efficacy measure is the proportion of participants that achieve HiSCR at Week 16
      with topical ruxolitinib 1.5% cream as compared to Week 0. The HiSCR is defined as an at
      least a 50% reduction in the total abscess and inflammatory nodule count (AN count) for all
      study body sites with no increase in abscess count and no increase in draining fistula count
      relative to Baseline. The primary efficacy analysis will be carried out on all participants
      who complete 16 weeks of treatment.

      The research study consists of an 8 week screening with 16 weeks open-label portion.
    
  